Cargando…
Regulatory T-cell therapy approaches
Regulatory T cells (Tregs) have enormous therapeutic potential to treat a variety of immunopathologies characterized by aberrant immune activation. Adoptive transfer of ex vivo expanded autologous Tregs continues to progress through mid- to late-phase clinical trials in several disease spaces and ha...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019137/ https://www.ncbi.nlm.nih.gov/pubmed/35960852 http://dx.doi.org/10.1093/cei/uxac078 |
_version_ | 1784907960624873472 |
---|---|
author | McCallion, Oliver Bilici, Merve Hester, Joanna Issa, Fadi |
author_facet | McCallion, Oliver Bilici, Merve Hester, Joanna Issa, Fadi |
author_sort | McCallion, Oliver |
collection | PubMed |
description | Regulatory T cells (Tregs) have enormous therapeutic potential to treat a variety of immunopathologies characterized by aberrant immune activation. Adoptive transfer of ex vivo expanded autologous Tregs continues to progress through mid- to late-phase clinical trials in several disease spaces and has generated promising preliminary safety and efficacy signals to date. However, the practicalities of this strategy outside of the clinical trial setting remain challenging. Here, we review the current landscape of regulatory T-cell therapy, considering emergent approaches and technologies presenting novel ways to engage Tregs, and reflect on the progress necessary to deliver their therapeutic potential to patients. |
format | Online Article Text |
id | pubmed-10019137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100191372023-03-17 Regulatory T-cell therapy approaches McCallion, Oliver Bilici, Merve Hester, Joanna Issa, Fadi Clin Exp Immunol Review Series: Therapeutic opportunities for regulatory T cell enhancing approaches (Series Editors: David F. Tough & Giovanna Lombardi) Regulatory T cells (Tregs) have enormous therapeutic potential to treat a variety of immunopathologies characterized by aberrant immune activation. Adoptive transfer of ex vivo expanded autologous Tregs continues to progress through mid- to late-phase clinical trials in several disease spaces and has generated promising preliminary safety and efficacy signals to date. However, the practicalities of this strategy outside of the clinical trial setting remain challenging. Here, we review the current landscape of regulatory T-cell therapy, considering emergent approaches and technologies presenting novel ways to engage Tregs, and reflect on the progress necessary to deliver their therapeutic potential to patients. Oxford University Press 2022-08-12 /pmc/articles/PMC10019137/ /pubmed/35960852 http://dx.doi.org/10.1093/cei/uxac078 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Series: Therapeutic opportunities for regulatory T cell enhancing approaches (Series Editors: David F. Tough & Giovanna Lombardi) McCallion, Oliver Bilici, Merve Hester, Joanna Issa, Fadi Regulatory T-cell therapy approaches |
title | Regulatory T-cell therapy approaches |
title_full | Regulatory T-cell therapy approaches |
title_fullStr | Regulatory T-cell therapy approaches |
title_full_unstemmed | Regulatory T-cell therapy approaches |
title_short | Regulatory T-cell therapy approaches |
title_sort | regulatory t-cell therapy approaches |
topic | Review Series: Therapeutic opportunities for regulatory T cell enhancing approaches (Series Editors: David F. Tough & Giovanna Lombardi) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019137/ https://www.ncbi.nlm.nih.gov/pubmed/35960852 http://dx.doi.org/10.1093/cei/uxac078 |
work_keys_str_mv | AT mccallionoliver regulatorytcelltherapyapproaches AT bilicimerve regulatorytcelltherapyapproaches AT hesterjoanna regulatorytcelltherapyapproaches AT issafadi regulatorytcelltherapyapproaches |